Once-daily Xibrom could be with us soon

Article

Results of a Phase III trial of the once-daily formulation of Xibrom (ISTA Pharmaceuticals) has found it to be both safe and efficacious.

Results of a Phase III trial of the once-daily formulation of Xibrom (ISTA Pharmaceuticals) for the treatment of ocular inflammation and pain associated with cataract surgery, has found it to be both safe and efficacious.

The multicentre study evaluated the once-daily formulation versus placebo in more than 500 patients who had undergone cataract surgery. Preliminary analyses of the results have found the safety profile to be consistent with the currently marketed twice-daily formulation of Xibrom.

ISTA plans to file a supplemental New Drug Application (sNDA) with the FDA during the second half of 2007.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Related Content
Topcon Healthcare, Inc. appoints Krysten Williams Head of Digital Solutions & Clinical Development – EMEA

Topcon Healthcare, Inc. appoints Krysten Williams Head of Digital Solutions & Clinical Development – EMEA

Sydney M Crago
May 9th 2025
Article

Williams joins Topcon Healthcare from Heidelberg Engineering, where she held multiple senior leadership roles.

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
Moorfields, Topcon, IoO announce partnership launch of Cascader

Moorfields, Topcon, IoO announce partnership launch of Cascader

Kassi Filkins
May 7th 2025
Article

Utilizing artificial intelligence (AI), Cascader is a new medical technology company that aims to transform the detection and management of eye disease.

An image of Salt Lake City. Historic downtown area. Concept image for 2025 Association for Research in Vision and Ophthalmology (ARVO). Image credit: ©pabrady63 – stock.adobe.com

Editorial Advisory Board members bring research findings to ARVO

Sydney M Crago
May 5th 2025
Article

Members of the Ophthalmology Times Europe, Ophthalmology Times and Modern Retina editorial advisory boards are present and presenting at the 2025 ARVO meeting

An image of an eye behind glasses. Digital input on the glasses conveys concept of artificial intelligence and computing. Image credit: ©Arsenii – stock.adobe.com

ZEISS debuts Research Data Platform, highlights Boehringer Ingelheim partnership

Martin David Harp
May 2nd 2025
Article

Carl Zeiss Meditec plans to launch the ZEISS RDP in select countries throughout 2025

LuxIA receives CE-MDR certification

LuxIA receives CE-MDR certification

Sydney M Crago
May 1st 2025
Article

LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.

© 2025 MJH Life Sciences

All rights reserved.